Tisagenlecleucel Infusion bulk supplier for pharma manufacturers

Tisagenlecleucel Infusion cells/kg patient Suppliers & Bulk Manufacturers

Available Forms: IV Infusion

Available Strengths: cells/kg patient

Reference Brands: Kymriah(US & EU)

Tisagenlecleucel is a CAR T-cell therapy that reprograms a patient's T cells to target and destroy CD19-positive cancer cells. It offers targeted treatment for refractory B-cell cancers, providing rapid remission, improved survival rates, and the potential for long-term disease control in leukemia and lymphoma patients when administered in specialized centers.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Tisagenlecleucel (Kymriah) is regulated in the EU and US, supported by dossiers demonstrating safety, efficacy, and manufacturing quality according to GMP and MDR standards. In the US, FDA approval involves extensive clinical validation for refractory B-cell malignancies, including safety monitoring. In the EU, CE marking certifies conformity with MDR regulations. These CAR T-cell therapies undergo validation, stability testing, and rigorous audits, with detailed documentation including clinical trial data, safety profiles, and manufacturing practices. For licensing procedures, approved dossiers, and the latest regulatory updates, visit Pharmatradz. Ensuring compliance guarantees access to innovative, effective immunotherapies supporting advanced cancer treatment worldwide.

Tisagenlecleucel Infusion — third party manufacturing & bulk supply

Tisagenlecleucel Infusion cells/kg patient is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Tisagenlecleucel Infusion is supplied as IV Infusion — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Tisagenlecleucel Infusion listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Tisagenlecleucel Infusion →

Back to Listing

Frequently Asked Questions

Tisagenlecleucel Infusion is listed as IV Infusion in cells/kg patient. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Tisagenlecleucel Infusion is referenced against Kymriah(US & EU). Reference brands are shown for identification only and remain the property of their respective trademark owners.